Eugia Pharma Specialities restarts production at terminally sterilized product lines

Eugia Pharma Specialities Limited has restarted production in its terminally sterilized product lines at its Unit-III, that was temporarily stopped to address some of the observations of USFDA in their recent inspection concluded on 2nd February 2024. We expect to start the production in the aseptic lines of the facility in the month of March 2024.

Eugia SEZ gets 7 observations from USFDA for injectable facility

The United States Food and Drug Administration (US FDA) inspected the injectable facility of Eugia SEZ Pvt. Ltd. (a 100% step-down subsidiary of Aurobindo Pharma Ltd.), situated at Polepally Village, Jadcherla Mandal, Mahaboobnagar District, Telangana, from 19th to 29th February 2024.

The inspection closed with 7 observations. The observations are procedural in nature and will be responded to within the stipulated time.